Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.

@article{Avril1996AssessmentOA,
  title={Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.},
  author={Norbert E Avril and Jorg Dose and F. J{\"a}nicke and Sibylle Ilse Ziegler and Wolfgang R{\"o}mer and Wolfgang Weber and M. Herz and Walter B. J. Nathrath and Henner Graeff and Markus Schwaiger},
  journal={Journal of the National Cancer Institute},
  year={1996},
  volume={88 17},
  pages={1204-9}
}
BACKGROUND The presence of metastatic tumor cells in the axillary lymph nodes is an important factor when deciding whether or not to treat breast cancer patients with adjuvant therapy. Positron emission tomography (PET) imaging with the radiolabeled glucose analogue 2-(fluorine-18)-fluoro-2-deoxy-D-glucose (F-18 FDG) has been used to visualize primary breast tumors as well as bone and soft-tissue metastases. PURPOSE This study was undertaken to evaluate before surgery the diagnostic accuracy… CONTINUE READING